<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073835</url>
  </required_header>
  <id_info>
    <org_study_id>142522</org_study_id>
    <nct_id>NCT05073835</nct_id>
  </id_info>
  <brief_title>Semaglutide 2.4 mg in Patients With Poor Weight-loss</brief_title>
  <acronym>BARI-STEP</acronym>
  <official_title>BARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients&#xD;
      with poor weight-loss following bariatric surgery. The primary aim of this trial is to&#xD;
      determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml&#xD;
      causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic&#xD;
      and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients&#xD;
      with poor weight loss following gastric bypass or sleeve gastrectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3b, double-blinded, randomised, parallel group trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blinded: both participants and study doctors will be blind to group allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>68 weeks</time_frame>
    <description>Percentage of total weight loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body weight reduction ≥10%</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the percentage of participants receiving subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo who after 68 weeks achieve a body weight reduction ≥10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight reduction ≥15%</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the percentage of participants receiving subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo who after 68 weeks achieve a body weight reduction ≥15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight reduction ≥20%</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the percentage of participants receiving subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo who after 68 weeks achieve a body weight reduction ≥20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating HbA1c levels</measure>
    <time_frame>68 weeks</time_frame>
    <description>The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating HbA1c levels in participants with pre-diabetes at baseline</measure>
    <time_frame>68 weeks</time_frame>
    <description>The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HbA1c in participants with pre-diabetes at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating HbA1c levels in participants with T2D at baseline</measure>
    <time_frame>68 weeks</time_frame>
    <description>The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HbA1c in participants with diabetes at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic BP</measure>
    <time_frame>68 weeks</time_frame>
    <description>The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic BP in participants with pre-existing hypertension</measure>
    <time_frame>68 weeks</time_frame>
    <description>The effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon BP in participants with pre-existing hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacological agents required for the management of hypertension</measure>
    <time_frame>68 weeks</time_frame>
    <description>The number of pharmacological agents required for the management of hypertension in participants with pre-existing hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating lipids</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon circulating lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating HsCRP and inflammatory cytokines</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in food craving scores assessed through power of food questionnaire</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon food cravings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HRQoL</measure>
    <time_frame>68 weeks</time_frame>
    <description>To compare the effect of 68 weeks of subcutaneous semaglutide 3.0 mg/ml at a dose of 2.4mg per week versus placebo administration upon HRQoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 levels</measure>
    <time_frame>68 weeks</time_frame>
    <description>To investigate the relationship between fasted and meal-stimulated active GLP-1 levels at baseline and %WL at 68 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration, once weekly, subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 3 mg</intervention_name>
    <description>Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients, ≥1 year primary RYGB or primary SG, with poor weight-loss (&lt;20% WL) that is&#xD;
             not caused by either a surgical or psychological problem.&#xD;
&#xD;
          2. Adults, 18-65 years inclusive.&#xD;
&#xD;
          3. Females of childbearing potential and female partners of male participants must be&#xD;
             willing to use highly effective method of contraception (hormonal or barrier method of&#xD;
             birth control; abstinence) (Appendix 2) from the time consent is signed until 2 months&#xD;
             after treatment discontinuation.&#xD;
&#xD;
          4. Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to randomisation. NOTE: Subjects are considered not of child bearing potential&#xD;
             if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral&#xD;
             tubal ligation, or bilateral oophorectomy) or they are postmenopausal.&#xD;
&#xD;
          5. A self-reported ≤5 % variation in body weight over preceding 3 months.&#xD;
&#xD;
          6. Fluent in English and able to understand and complete questionnaires.&#xD;
&#xD;
          7. Participants capable to provide written informed consent and comply with the trial&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bariatric surgical procedure other than RYGB and SG, or revision bariatric surgery of&#xD;
             any operation type.&#xD;
&#xD;
          2. Personal history of type I diabetes or type II diabetes mellitus currently treated&#xD;
             with insulin.&#xD;
&#xD;
          3. Concomitant use of GLP-1R agonist or DPPIV-inhibitors.&#xD;
&#xD;
          4. Female who is pregnant, breast-feeding, or intends to become pregnant.&#xD;
&#xD;
          5. Current participation in other clinical intervention trial.&#xD;
&#xD;
          6. History of suicidal attempt in the previous 5 years or untreated severe depression or&#xD;
             mental health condition assessed by direct questioning.&#xD;
&#xD;
          7. Symptomatic gallstone disease&#xD;
&#xD;
          8. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood&#xD;
             pressure ≥ 100 mmHg).&#xD;
&#xD;
          9. Renal impairment measured as glomerular infiltration rate (eGFR &lt;15 ml/min 1.73 m2&#xD;
&#xD;
         10. Known or suspected hypersensitivity to semaglutide or any of the excipients involved&#xD;
             in their formulation.&#xD;
&#xD;
         11. Personal or family history of medullary thyroid carcinoma or multiple endocrine&#xD;
             neoplasia syndrome type 2.&#xD;
&#xD;
         12. History of malignant neoplasms within the past 5 years prior to screening. Basal and&#xD;
             squamous cell skin cancer and any carcinoma in-situ are allowed.&#xD;
&#xD;
         13. Personal history of acute pancreatitis 180 days before screening or chronic&#xD;
             pancreatitis.&#xD;
&#xD;
         14. Uncontrolled thyroid disease.&#xD;
&#xD;
         15. History of stroke, unstable angina, acute coronary syndrome, congestive heart failure&#xD;
             New York Heart Association class III-IV within the preceding 12 months.&#xD;
&#xD;
         16. Untreated clinically significant arrhythmias.&#xD;
&#xD;
         17. Diabetic gastroparesis.&#xD;
&#xD;
         18. Concomitant usage of medications that cause weight gain or weight loss.&#xD;
&#xD;
         19. Known or suspected abuse of alcohol or recreational drugs.&#xD;
&#xD;
         20. Severe hepatic impairment diagnosed via liver function blood tests and clinical&#xD;
             evaluation&#xD;
&#xD;
         21. Any additional factor, which in the investigator's opinion, might jeopardise the&#xD;
             subject's safety or compliance with the trial protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel L Batterham</last_name>
    <phone>02076790991</phone>
    <email>r.batterham@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alisia Carnemolla</last_name>
    <phone>02076796308</phone>
    <email>a.carnemolla@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCL</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel L Batterham</last_name>
      <email>r.batterham@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>diabetes</keyword>
  <keyword>semaglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

